New Releases from NCBI BookshelfRuxolitinib (Opzelura): Indication: For the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable: Reimbursement Recommendation [Internet].​Ruxolitinib (Opzelura): Indication: For the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable: Reimbursement Recommendation [Internet].